Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Investor update summary9 Mar, 2026
Strategic and Market Outlook
Peak sales opportunity for Gazyva in immune-mediated diseases is estimated at above $2 billion, with current consensus for 2030 at CHF 1.7 billion, indicating further upside potential.
Market for SLE, lupus nephritis, membranous nephropathy, and IgAN in US, EU5, and Japan expected to more than double from $5 billion in 2025 to $11.4 billion by 2030, driven by new therapies and high unmet needs.
Sefaxersen in IgAN now included in most analyst models, with CHF 400 million forecasted sales by 2030; peak potential seen at $1–2 billion.
Giredestrant sales expectations increased to $3.2 billion by 2030, while fenebrutinib in MS is forecasted at $1.1 billion.
Additional upside expected as new data are presented and launches approach.
Strategic Focus and Pipeline Overview
Aims to become a global leader in immune-mediated kidney and rheumatological diseases, focusing on long-lasting remission and reducing treatment burden.
Pipeline includes multiple assets targeting SLE, LN, MN, INS, IgAN, and aHUS, with several Phase III trials and filings expected in 2026.
Multiple innovative approaches in development, including B-cell depletion, complement inhibition, bispecifics, and allogeneic CAR-T therapies.
Immunology Pipeline and Innovation
Focus on B-cell-targeted therapies and complement inhibition to induce long-lasting remission in immune-mediated kidney and rheumatologic diseases.
Gazyva, sefaxersen, and other B-cell depleting agents, including bispecifics and CAR-Ts, are in development for chronic autoimmune diseases.
Afimkimab (TL1A antibody) in Phase II/III for multiple indications, with Phase B readouts in UC and CD expected in 2027.
New NME in IBD initiated in Phase I; NLRP3 inhibitor in asthma and broader programs in neurology and cardiovascular diseases ongoing.
Multiple B-cell depletion strategies in development, including bispecifics and allogeneic CAR-T, with ongoing and planned clinical studies.
Explain Gazyva's glycoengineering vs Type I mAbs
Describe Sefaxersen's complement suppression MoA
Detail PiaSky recycling tech and dosing benefits
Inclusion of DORIS remission data in Gazyva label
Rationale for allogeneic over autologous CAR T
Gazyva IV competitiveness versus subcu and orals
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I’m actually shocked at just how much I like Quartr. If you’re an analyst & need a strong web tool + mobile app that syncs properly, saves you from manually dialing into calls.
@endthepods x.com
A must have for every investor. includes all quarterly reports with earnings calls and transcripts in single app
Abdulla AlnaamaGoogle Play
Efficient UI/UX. Prior to Quartr I didn’t spend enough time on earnings calls. The features and UI make easy to dedicate time getting in the weeds using transcripts.
YJhLoApp Store
I’m actually shocked at just how much I like Quartr. If you’re an analyst & need a strong web tool + mobile app that syncs properly, saves you from manually dialing into calls.
@endthepods x.com
A must have for every investor. includes all quarterly reports with earnings calls and transcripts in single app
Abdulla AlnaamaGoogle Play
Efficient UI/UX. Prior to Quartr I didn’t spend enough time on earnings calls. The features and UI make easy to dedicate time getting in the weeds using transcripts.
Roche Holding AG, commonly referred to as Roche is a Swiss multinational healthcare company with a rich history dating back to 1896. From its headquarters in Basel, Roche is active with operations in pharmaceuticals and diagnostics, with aportfolio spanning oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. As one of the largest healthcare companies globally, Roche's products and services reach millions of people all over the globe.
From Humble Origins to Global Impact
Founded by Fritz Hoffmann-La Roche, Roche started as a small drug factory but quickly grew to become a leading player in the pharmaceutical industry. In its early years, Roche distinguished itself through its focus on innovation and international outlook, becoming the first company to mass-produce synthetic vitamin C in the 1930s. The company's focus on innovation and the development of new medicines has not wavered since its inception. Roche's pharmaceutical pipeline remains a critical factor in its ongoing growth, continually reinforcing its position as an important player in global healthcare.
What They Do
The company develops and provides innovative healthcare solutions, with a significant emphasis on oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Its pharmaceutical division works to research, develop, and market medications. Simultaneously, its diagnostics division delivers insights into diseases, providing doctors with tools for early detection, targeted treatment, and patient monitoring. Roche is a pioneer in integrated healthcare solutions, deeply investing in genomics and data analytics, underpinning its commitment to personalized medicine. As a global pharmaceutical and healthcare company they compete with names like Novartis, Pfizer, Novo Nordisk, and many others.
Strategic Acquisitions
The company is deeply invested in advancing the understanding and treatment of diseases through genetic insights. This commitment can be exemplified in its acquisition of Foundation Medicine and Flatiron Health, companies specializing in cancer genomics and real-world evidence solutions, respectively. These acquisitions supplement Roche's in-house efforts to develop therapies targeting the genetic drivers of disease.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
)
)
)
)
)
)